The success of combination therapy in hormone receptor-positive and HER2-expressing breast cancers, and the clear need for better therapy options in TNBC, provide a strong rationale for continued study of the use of FOXM1 inhibitors in combination with other drugs. Here, FOXM1 is linked to breast carcinoma.